MENVEO DIN 02563029
Status: Marketed
Holder: GLAXOSMITHKLINE INC
Molecule: MENINGOCOCCAL GROUP A OLIGOSACCHARIDE
Available to quote
Health Canada record
| Active ingredient(s) | MENINGOCOCCAL GROUP A OLIGOSACCHARIDE 10 MCG; MENINGOCOCCAL GROUP C OLIGOSACCHARIDE 5 MCG; MENINGOCOCCAL GROUP W-135 OLIGOSACCHARIDE 5 MCG; MENINGOCOCCAL GROUP Y OLIGOSACCHARIDE 5 MCG |
|---|---|
| Dosage form | Solution |
| Route | Intramuscular |
| Schedule | SCHEDULE D |
| Class | Human |
| ATC | J07AH08 MENINGOCOCCUS, A, C, Y, W-135, TETRAVAL. PURIFIED POLYSACC. ANTIGEN CONJUGATED |
| Original market date | 13-Apr-2026 |
| Current status date | 13-Apr-2026 |
| Source | Health Canada DPD |
Establishment licence of the holder
GlaxoSmithKline Inc. — licence 100630, currently licensed, last inspection rating C (2025-09-15).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing MENINGOCOCCAL GROUP A OLIGOSACCHARIDE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02347393 | MENVEO | GLAXOSMITHKLINE INC | Powder For Solution; Solution | MENINGOCOCCAL GROUP A OLIGOSACCHARIDE 10 MCG; MENINGOCOCCAL GROUP C OLIGOSACCHARIDE 5 MCG; MENINGOCOCCAL GROUP W-135 OLIGOSACCHARIDE 5 MCG; MENINGOCOCCAL GROUP Y OLIGOSACCHARIDE 5 MCG; CORYNEBACTERIUM DIPHTHERIAE CRM-197 PROTEIN 47 MCG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 36545 | 2025-11-21 | Supplement to a New Drug Submission (SNDS) | Addition of a new dosage form |